CompanyKZIANasdaqSydney Nsw

Kazia Therapeutics Ltd

Kazia Therapeutics develops paxalisib, a brain-penetrant PI3K/Akt/mTOR pathway inhibitor for multiple cancers including glioblastoma, breast cancer, brain metastases, and diffuse midline gliomas.

Stories only

SEC EDGAR ClinicalTrials.gov kaziatx.com

10-KSep 25Latest SEC filing

Sep 22Latest story

September 2026

Sovargen doses first patient in paxalisib epilepsy trial, triggers $2M payment to Kazia

Sep 22Trial updateKazia Therapeutics Ltd

August 2026

Kazia files final prospectus, discloses new details on TNBC data and share count after $40M offering

Aug 31FinancingKazia Therapeutics Ltd